Literature DB >> 33878036

Enhanced triacylglycerol catabolism by Carboxylesterase 1 promotes aggressive colorectal carcinoma.

Daria Capece1, Daniel D'Andrea1, Federica Begalli1, Laura Goracci2, Laura Tornatore1, James L Alexander3, Alessandra Di Veroli2, Shi-Chi Leow4, Thamil S Vaiyapuri5, James K Ellis6, Daniela Verzella1, Jason Bennett1, Luca Savino7, Yue Ma8, James S McKenzie6, Maria Luisa Doria6, Sam E Mason6, Kern Rei Chng9, Hector C Keun6, Gary Frost8, Vinay Tergaonkar5, Katarzyna Broniowska10, Walter Stunkel11, Zoltan Takats6, James M Kinross6, Gabriele Cruciani2, Guido Franzoso1.   

Abstract

The ability to adapt to low-nutrient microenvironments is essential for tumor-cell survival and progression in solid cancers, such as colorectal carcinoma (CRC). Signaling by the NF-κB transcription-factor pathway associates with advanced disease stages and shorter survival in CRC patients. NF-κB has been shown to drive tumor-promoting inflammation, cancer-cell survival and intestinal epithelial cell (IEC) dedifferentiation in mouse models of CRC. However, whether NF-κB affects the metabolic adaptations that fuel aggressive disease in CRC patients is unknown. Here, we identified carboxylesterase 1 (CES1) as an essential NF-κB-regulated lipase linking obesity-associated inflammation with fat metabolism and adaptation to energy stress in aggressive CRC. CES1 promoted CRC-cell survival via cell-autonomous mechanisms that fuel fatty-acid oxidation (FAO) and prevent the toxic build-up of triacylglycerols. We found that elevated CES1 expression correlated with worse outcomes in overweight CRC patients. Accordingly, NF-κB drove CES1 expression in CRC consensus molecular subtype (CMS)4, associated with obesity, stemness and inflammation. CES1 was also upregulated by gene amplifications of its transcriptional regulator, HNF4A, in CMS2 tumors, reinforcing its clinical relevance as a driver of CRC. This subtype-based distribution and unfavourable prognostic correlation distinguished CES1 from other intracellular triacylglycerol lipases and suggest CES1 could provide a route to treat aggressive CRC.

Entities:  

Keywords:  Colorectal cancer; Metabolism; NF-kappaB; Oncology

Year:  2021        PMID: 33878036     DOI: 10.1172/JCI137845

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  5 in total

1.  CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma.

Authors:  Jing Wang; Yan Zhou; Donghui Zhang; Weiyi Zhao; Yishi Lu; Chaoqun Liu; Wandie Lin; Yujie Zhang; Kunling Chen; Hui Wang; Liang Zhao
Journal:  EMBO J       Date:  2022-07-01       Impact factor: 14.012

2.  Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel Disease.

Authors:  Ahmed M I Elfiky; Mohammed Ghiboub; Andrew Y F Li Yim; Ishtu L Hageman; Jan Verhoeff; Manon de Krijger; Patricia H P van Hamersveld; Olaf Welting; Iris Admiraal; Shafaque Rahman; Juan J Garcia-Vallejo; Manon E Wildenberg; Laura Tomlinson; Richard Gregory; Inmaculada Rioja; Rab K Prinjha; Rebecca C Furze; Huw D Lewis; Palwinder K Mander; Sigrid E M Heinsbroek; Matthew J Bell; Wouter J de Jonge
Journal:  J Crohns Colitis       Date:  2022-05-10       Impact factor: 10.020

Review 3.  Cancer metabolism and dietary interventions.

Authors:  Lin Qian; Fan Zhang; Miao Yin; Qunying Lei
Journal:  Cancer Biol Med       Date:  2021-12-22       Impact factor: 4.248

4.  Rewired lipid metabolism as an actionable vulnerability of aggressive colorectal carcinoma.

Authors:  Daria Capece; Guido Franzoso
Journal:  Mol Cell Oncol       Date:  2022-01-27

Review 5.  The role of hepatocyte nuclear factor 4α (HNF4α) in tumorigenesis.

Authors:  Lei Sang; Xingshun Wang; Weiyu Bai; Junling Shen; Yong Zeng; Jianwei Sun
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.